Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Top Research Reports for Abbott, Netflix & Philip Morris

Top Research Reports for Abbott, Netflix & Philip Morris

NFLX : 315.10 (-3.11%)
ABT : 87.49 (-0.31%)
UTX : 132.39 (+0.83%)
NVS : 93.56 (-0.74%)
PM : 88.73 (+1.16%)
BMY : 43.33 (-1.63%)
Anti-Epileptic Drugs For Pediatrics Market: Newer Drug Therapies With Symptom Specific Indications

Anti-epileptics drugs for pediatrics treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare...

VRX.TO : 30.80 (-3.33%)
NVS : 93.56 (-0.74%)
GSK : 40.96 (-1.09%)
PFE : 42.77 (-0.67%)
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

AZN : 40.12 (-1.50%)
MRK : 81.39 (-1.57%)
JNJ : 130.31 (-1.33%)
AGN : 163.16 (+0.68%)
NVS : 93.56 (-0.74%)
ABBV : 68.54 (+0.42%)
GSK : 40.96 (-1.09%)
Keloid Treatment Market 2019|Top Key Players Analysis, Trends, Global Size Forecast To 2024

The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pacific...

VRX.TO : 30.80 (-3.33%)
GALE : 0.26 (-7.14%)
AVMXY : 6.0800 (+2.18%)
NVS : 93.56 (-0.74%)
SNOA : 6.18 (-0.96%)
GSK : 40.96 (-1.09%)
BMY : 43.33 (-1.63%)
PRGO : 51.56 (+0.29%)
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus,...

NVS : 93.56 (-0.74%)
GILD : 65.04 (-3.23%)
Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma

STOCKHOLM - July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made...

NVS : 93.56 (-0.74%)
Sunstone Life Science Ventures Joins Forendo Pharma Investor Syndicate

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that Sunstone Life Science Ventures has made a EUR 5 million investment in Forendo....

NVS : 93.56 (-0.74%)
Medicxi Closes a New EUR400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters

Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new EUR400 million fund. This brings the total amount raised by Medicxi in the last three years to over...

ADPT : 38.53 (+1.37%)
NVS : 93.56 (-0.74%)
NERV : 6.53 (+0.62%)
Netflix, United Rentals fall while Union Pacific, eBay rise

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:

ASH : 76.11 (+0.81%)
UNP : 175.30 (+0.60%)
NVS : 93.56 (-0.74%)
URI : 118.98 (-1.76%)
PM : 88.73 (+1.16%)
Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.

MRK : 81.39 (-1.57%)
AGN : 163.16 (+0.68%)
NVS : 93.56 (-0.74%)
GSK : 40.96 (-1.09%)
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

MRK : 81.39 (-1.57%)
NVS : 93.56 (-0.74%)
ABBV : 68.54 (+0.42%)
RHHBY : 33.6401 (-2.41%)
Novartis: 2Q Earnings Snapshot

BASEL, Switzerland (AP) _ Novartis AG (NVS) on Thursday reported second-quarter earnings of $6.8 billion.

NVS : 93.56 (-0.74%)
LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating rare diseases with few or no therapeutic options, today announced that the Food & Drug Administration (FDA) granted rare pediatric...

IPXL : 18.30 (unch)
NVS : 93.56 (-0.74%)
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

Novartis International AG / Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased . Processed...

NVS : 93.56 (-0.74%)
Epilepsy Therapeutic Market SWOT Analysis | Key Players- Abbott, GlaxoSmithKline, UCB, Cephalon, Johnson & Johnson, Pfizer, Novartis

A new research study from HTF MI with title provides an in-depth assessment of the Epilepsy Therapeutic including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies,...

VRX.TO : 30.80 (-3.33%)
ABT : 87.49 (-0.31%)
NVS : 93.56 (-0.74%)
GSK : 40.96 (-1.09%)
Why Earnings Season Could Be Great for Novartis (NVS)

Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NVS : 93.56 (-0.74%)
Myasthenia Gravis Treatment Market to see strong growth and various Market opportunities during forecasts period...

VRX.TO : 30.80 (-3.33%)
NVS : 93.56 (-0.74%)
ABBV : 68.54 (+0.42%)
TEVA : 7.91 (+1.02%)
GSK : 40.96 (-1.09%)
BMY : 43.33 (-1.63%)
Trade Talk Cools Off Record-Setting Market

Trade Talk Cools Off Record-Setting Market

NFLX : 315.10 (-3.11%)
YNDX : 39.00 (-1.54%)
WWE : 70.23 (+0.04%)
YETI : 32.87 (+2.08%)
NVS : 93.56 (-0.74%)
VSLR : 8.16 (-2.16%)
GDI : 33.53 (+2.29%)
OGI : 6.33 (-1.56%)
WDC : 52.46 (-0.79%)
SPLK : 138.14 (-0.18%)
ZBRA : 182.15 (-0.30%)
TRHC : 54.78 (-0.65%)
SPWR : 10.99 (+0.73%)
PANW : 222.26 (-0.02%)
Should You Pick Up Novartis (NVS) Before Q2 Earnings?

Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should...

CRSP : 49.04 (-1.37%)
RCDTF : 34.7000 (-0.48%)
VRTX : 174.13 (-2.22%)
GBT : 55.56 (-3.36%)
ALC : 60.08 (-1.35%)
NVS : 93.56 (-0.74%)
PFE : 42.77 (-0.67%)
Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?

Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.

MRK : 81.39 (-1.57%)
AGN : 163.16 (+0.68%)
NVS : 93.56 (-0.74%)
BMY : 43.33 (-1.63%)

Van Meerten Stock Picks

Leading Economic Indicator ALERT!
I very closely follow the Conference Board's Leading Economic Indicators.
IVV -1.75
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar